Table 1. Patient characteristics and... | Rockefeller University Press

Table 1.

Patient characteristics and outcomes

Patient	Age/Sex		Donor type	Conditioning regimen	Stem cell (CD34 cells) dose per kg of recipient	Post-HSCT outcome
1	3 mo/male	IFN-γ	Haplo	Flu/Treo/PTCy	5 million	Graft rejection/alive
2	5 years/male	IFN-γ	MFD	Flu/Treo/TT	5 million	Graft rejection/dead
3	3 years/female	IFN-γ	MSD	Flu/Treo/TT	10 million	Complete donor chimerism/alive
4	2.5 years/female	IFN-γ	Haplo	Flu/Treo/TT TCRαβ depletion	10 million	Complete donor chimerism/alive
1	6 years/male (second HSCT)	IFN-γ	Haplo	Flu/Treo/TT TCRαβ depletion	10 million	Mixed chimerism—improved after graded whole blood DLI/alive
5	5 years/male	IL-12	MFD	Flu/Treo	7 million	Complete donor chimerism/alive
6	10 years/male	IL-12	Haplo	Flu/Treo/2 Gy TBI/PTCy	8 million	Complete donor chimerism/alive
7	6 years/female	IL-12	Haplo	Flu/Treo/PTCy	8 million	Mixed chimerism—improved after graded whole blood DLI/alive

Patient	Age/Sex		Donor type	Conditioning regimen	Stem cell (CD34 cells) dose per kg of recipient	Post-HSCT outcome
1	3 mo/male	IFN-γ	Haplo	Flu/Treo/PTCy	5 million	Graft rejection/alive
2	5 years/male	IFN-γ	MFD	Flu/Treo/TT	5 million	Graft rejection/dead
3	3 years/female	IFN-γ	MSD	Flu/Treo/TT	10 million	Complete donor chimerism/alive
4	2.5 years/female	IFN-γ	Haplo	Flu/Treo/TT TCRαβ depletion	10 million	Complete donor chimerism/alive
1	6 years/male (second HSCT)	IFN-γ	Haplo	Flu/Treo/TT TCRαβ depletion	10 million	Mixed chimerism—improved after graded whole blood DLI/alive
5	5 years/male	IL-12	MFD	Flu/Treo	7 million	Complete donor chimerism/alive
6	10 years/male	IL-12	Haplo	Flu/Treo/2 Gy TBI/PTCy	8 million	Complete donor chimerism/alive
7	6 years/female	IL-12	Haplo	Flu/Treo/PTCy	8 million	Mixed chimerism—improved after graded whole blood DLI/alive

MSD, matched sibling donor; TBI, total body irradiation.